Hutton J T, Dippel R L, Bianchine J R, Strahlendorf H K, Meyer P G
Clin Neuropharmacol. 1984;7(2):135-9. doi: 10.1097/00002826-198406000-00003.
Controlled release carbidopa/levodopa (CSR-1) was compared to standard carbidopa/levodopa in a double-blind, crossover study of 20 Parkinson's disease patients. The most consistent finding in a variety of clinical measurements was the superiority of standard carbidopa/levodopa to CSR-1. Increased dosages of CSR-1 resulted in reduced Parkinson symptoms, suggesting that a more potent controlled-release formulation might prove to be more efficacious than CSR-1.
在一项针对20名帕金森病患者的双盲交叉研究中，将控释卡比多巴/左旋多巴（CSR-1）与标准卡比多巴/左旋多巴进行了比较。在各种临床测量中最一致的发现是标准卡比多巴/左旋多巴优于CSR-1。增加CSR-1的剂量可减轻帕金森症状，这表明一种更有效的控释制剂可能比CSR-1更有效。
